Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01761383
Other study ID # 6006092
Secondary ID
Status Completed
Phase N/A
First received November 1, 2012
Last updated February 11, 2016
Start date June 2012
Est. completion date January 2015

Study information

Verified date February 2016
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the use of Nintendo Wii will help improve negative symptoms of Schizophrenia and quality of life of patients with chronic Schizophrenia.


Description:

The proposed study seeks to determine whether any benefit in daily functioning and quality of life can be gained from using the Nintendo Wii video game console in chronic mental illness, namely schizophrenia. There is a small research base on the use of the Wii console in elderly nursing home residents as a means of increasing mobility, with attendant benefits in areas such as falls, quality of life, and relief of subsyndromal depression. For individuals with schizophrenia, adjunct exercise therapy has been associated with gains in both psychiatric and physical symptoms. However, people with schizophrenia face physical and functional barriers in initiating and continuing organized activity programs. Thus, the Nintendo Wii Fit Plus interactive fitness video game is being proposed as a novel way of introducing and engaging people with schizophrenia in various forms of physical activity.

As the first study to assess the use of the Nintendo Wii in chronic mental illness, the purpose of this pilot study is to assess the feasibility and the capacity of the Nintendo Wii in improving the health and functioning of people with severe, chronic schizophrenia. Although it is hypothesized that Nintendo Wii use will lead to gains in these domains, the information gained from this study will be used to determine specific areas of benefit and to assess whether any observed differences in outcome measures are sufficient to warrant a full-scale study. Furthermore, this initial study aims to pilot the interview schedule, clarify wording on the questionnaires, ensure that all important areas have been covered by the questionnaires, and determine whether participants are capable of meeting the demands of the study.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients diagnosed with Schizophrenia defined by the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision)

- Males or females aged 18 years of older

- Participate in the Community High Intensity Treatment Team (CHITT) out-patient program

- Certified by their physician to participate in physical activity

Exclusion Criteria:

- History of violence or other risks that may endanger study research assistants during home visits

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Nintendo Wii video console and Nintendo Wii Fit Plus games
The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.

Locations

Country Name City State
Canada Community High Intensity Treatment Team (CHITT) at Providence Care Mental Health Services Kingston Ontario

Sponsors (2)

Lead Sponsor Collaborator
Queen's University Walmart Canada Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life. To assess whether any benefit in daily functioning and quality of life can be gained from using the Nintendo Wii video game console in people with chronic Schizophrenia. Assessed with the use of Short Form (36 questions)self report Health Survey (SF-36), Global Assessment of Functioning (GAF) Scale and the Clinical Global Impression-Schizophrenia(CGI-SCH)Scale. 6 months No
Secondary Weight. To assess whether the use of Nintendo Wii will help in weight reduction [assessed using Body Mass Index (BMI) calculations and weight measurements] in patients with Chronic Schizophrenia. 6 months No
Secondary Subjective overall functioning. To assess whether the use of Nintendo Wii will help to: reduce cigarette consumption, improve subjective quality of life and motivation [assessed using a self report Visual Analog Scale(VAS)] in patients with Chronic Schizophrenia. 6 months No
See also
  Status Clinical Trial Phase
Completed NCT00161044 - An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms N/A
Completed NCT01450514 - POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia Phase 2
Completed NCT05809882 - Study of Experience of High-frequency Repetitive Transcranial N/A
Recruiting NCT05948696 - Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
Completed NCT06206798 - Resourcefulness Group Intervention on Recovery and Quality of Life N/A
Completed NCT01891929 - Cognitive Remediation and Sheltered Employment in Schizophrenia N/A
Completed NCT03275909 - Integrated Psychological Therapy for Chronic Schizophrenia N/A
Completed NCT02298985 - Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Phase 4
Recruiting NCT00525863 - Oxygen Therapy in Schizophrenia Phase 3
Completed NCT02624167 - A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia Phase 2
Completed NCT00789698 - Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia Phase 3
Recruiting NCT06349369 - Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia N/A
Completed NCT02421146 - The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study N/A
Active, not recruiting NCT00664274 - Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia N/A
Terminated NCT00148616 - Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia Phase 3